Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Not yet recruiting · NCT07494435 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Not yet recruiting | Phase 2 | 2026-03-27 | NCT07494435 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang Haichang Biotech Co., Ltd. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| China Pharmaceutical University, Shanghai Gobroad Cancer Hospital | Shanghai | China | 2 |